107 research outputs found
International Survey on Diagnostic and Prognostic Procedures in Pediatric Disorders of Consciousness
Towards a Biomarker of Motor Adaptation: Integration of Kinematic and Neural Factors
We propose an experimental protocol for the integrated study of motor adaptation during target-based movements. We investigated how motor adaptation affects both cerebral activity and motor performance during the preparation and execution of a pointing task, under different conditions of external perturbation. Electroencephalography (EEG) and movement analysis were simultaneously recorded from 16 healthy subjects enrolled in the study. EEG signal was preprocessed bymeans of independent
component analysis and empirical mode decomposition
based Hilbert Huang transform, in order to extract event-related
synchronization (ERS) and desynchronization (ERD) parameters.
Movement analysis provided several kinematic indexes, such as
movement durations, average jerk, and inter-quartile-ranges.
Significant correlations between score, neural, and kinematic
parameters were found. Specifically, the duration of the going
phase of movement was found to correlate with synchronization in
the beta brain rhythm, in both the planning and executive phases
of movement. Inter-quartile ranges and average jerk showed correlations with executive brain parameters and ERS/ERDcueBeta, respectively. Results indicate the presence of links between the primary motor cortex and the farthest ending point of the upper limb. In the present study, we assessed significant relationship between neural and kinematic descriptors of motor adaptation, during a protocol requiring short-term learning, through the modulation of the external perturbations
Deep and surface hemodynamic signal from functional time resolved transcranial near infrared spectroscopy compared to skin flowmotion
n/
Treatment of T3-T4a laryngeal cancer by open partial horizontal laryngectomies: prognostic impact of different pT subcategories
Author Correction: Symptoms and syndromes associated with SARS-CoV-2 infection and severity in pregnant women from two community cohorts
Correction to: Scientific Reports https://doi.org/10.1038/s41598-021-86452-3, published online 25 March 2021
The Funding section in the original version of this Article was incomplete
Accessible Data Curation and Analytics for International-Scale Citizen Science Datasets
The Covid Symptom Study, a smartphone-based surveillance study on COVID-19
symptoms in the population, is an exemplar of big data citizen science. Over
4.7 million participants and 189 million unique assessments have been logged
since its introduction in March 2020. The success of the Covid Symptom Study
creates technical challenges around effective data curation for two reasons.
Firstly, the scale of the dataset means that it can no longer be easily
processed using standard software on commodity hardware. Secondly, the size of
the research group means that replicability and consistency of key analytics
used across multiple publications becomes an issue. We present ExeTera, an open
source data curation software designed to address scalability challenges and to
enable reproducible research across an international research group for
datasets such as the Covid Symptom Study dataset
The effects of COVID-19 on cognitive performance in a community-based cohort: a COVID symptom study biobank prospective cohort study
BACKGROUND:
Cognitive impairment has been reported after many types of infection, including SARS-CoV-2. Whether deficits following SARS-CoV-2 improve over time is unclear. Studies to date have focused on hospitalised individuals with up to a year follow-up. The presence, magnitude, persistence and correlations of effects in community-based cases remain relatively unexplored.
METHODS:
Cognitive performance (working memory, attention, reasoning, motor control) was assessed in a prospective cohort study of participants from the United Kingdom COVID Symptom Study Biobank between July 12, 2021 and August 27, 2021 (Round 1), and between April 28, 2022 and June 21, 2022 (Round 2). Participants, recruited from the COVID Symptom Study smartphone app, comprised individuals with and without SARS-CoV-2 infection and varying symptom duration. Effects of COVID-19 exposures on cognitive accuracy and reaction time scores were estimated using multivariable ordinary least squares linear regression models weighted for inverse probability of participation, adjusting for potential confounders and mediators. The role of ongoing symptoms after COVID-19 infection was examined stratifying for self-perceived recovery. Longitudinal analysis assessed change in cognitive performance between rounds.
FINDINGS:
3335 individuals completed Round 1, of whom 1768 also completed Round 2. At Round 1, individuals with previous positive SARS-CoV-2 tests had lower cognitive accuracy (N = 1737, β = −0.14 standard deviations, SDs, 95% confidence intervals, CI: −0.21, −0.07) than negative controls. Deficits were largest for positive individuals with ≥12 weeks of symptoms (N = 495, β = −0.22 SDs, 95% CI: −0.35, −0.09). Effects were comparable to hospital presentation during illness (N = 281, β = −0.31 SDs, 95% CI: −0.44, −0.18), and 10 years age difference (60–70 years vs. 50–60 years, β = −0.21 SDs, 95% CI: −0.30, −0.13) in the whole study population. Stratification by self-reported recovery revealed that deficits were only detectable in SARS-CoV-2 positive individuals who did not feel recovered from COVID-19, whereas individuals who reported full recovery showed no deficits. Longitudinal analysis showed no evidence of cognitive change over time, suggesting that cognitive deficits for affected individuals persisted at almost 2 years since initial infection.
INTERPRETATION:
Cognitive deficits following SARS-CoV-2 infection were detectable nearly two years post infection, and largest for individuals with longer symptom durations, ongoing symptoms, and/or more severe infection. However, no such deficits were detected in individuals who reported full recovery from COVID-19. Further work is needed to monitor and develop understanding of recovery mechanisms for those with ongoing symptoms.
FUNDING:
Chronic Disease Research Foundation, Wellcome Trust, National Institute for Health and Care Research, Medical Research Council, British Heart Foundation, Alzheimer's Society, European Union, COVID-19 Driver Relief Fund, French National Research Agency
Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study
BACKGROUND: The SARS-CoV-2 variant of concern, omicron, appears to be less severe than delta. We aim to quantify the differences in symptom prevalence, risk of hospital admission, and symptom duration among the vaccinated population. METHODS: In this prospective longitudinal observational study, we collected data from participants who were self-reporting test results and symptoms in the ZOE COVID app (previously known as the COVID Symptoms Study App). Eligible participants were aged 16-99 years, based in the UK, with a body-mass index between 15 and 55 kg/m2, had received at least two doses of any SARS-CoV-2 vaccine, were symptomatic, and logged a positive symptomatic PCR or lateral flow result for SARS-CoV-2 during the study period. The primary outcome was the likelihood of developing a given symptom (of the 32 monitored in the app) or hospital admission within 7 days before or after the positive test in participants infected during omicron prevalence compared with those infected during delta prevalence. FINDINGS: Between June 1, 2021, and Jan 17, 2022, we identified 63 002 participants who tested positive for SARS-CoV-2 and reported symptoms in the ZOE app. These patients were matched 1:1 for age, sex, and vaccination dose, across two periods (June 1 to Nov 27, 2021, delta prevalent at >70%; n=4990, and Dec 20, 2021, to Jan 17, 2022, omicron prevalent at >70%; n=4990). Loss of smell was less common in participants infected during omicron prevalence than during delta prevalence (16·7% vs 52·7%, odds ratio [OR] 0·17; 95% CI 0·16-0·19, p<0·001). Sore throat was more common during omicron prevalence than during delta prevalence (70·5% vs 60·8%, 1·55; 1·43-1·69, p<0·001). There was a lower rate of hospital admission during omicron prevalence than during delta prevalence (1·9% vs 2·6%, OR 0·75; 95% CI 0·57-0·98, p=0·03). INTERPRETATION: The prevalence of symptoms that characterise an omicron infection differs from those of the delta SARS-CoV-2 variant, apparently with less involvement of the lower respiratory tract and reduced probability of hospital admission. Our data indicate a shorter period of illness and potentially of infectiousness which should impact work-health policies and public health advice. FUNDING: Wellcome Trust, ZOE, National Institute for Health Research, Chronic Disease Research Foundation, National Institutes of Health, and Medical Research Council
- …